- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Foster City Today
By the People, for the People
Sumitomo Mitsui Trust Group Reduces Gilead Sciences Stake
Institutional investor lowers position in major biotech company
Apr. 12, 2026 at 10:53am
Got story updates? Submit your updates here. ›
The inner workings of a leading biotech firm, where institutional investors closely monitor the gears of finance and innovation.Foster City TodaySumitomo Mitsui Trust Group Inc. lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 1.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,269,117 shares of the biopharmaceutical company's stock after selling 60,405 shares during the period.
Why it matters
Gilead Sciences is a major player in the biopharmaceutical industry, particularly in the areas of antiviral therapies for HIV and viral hepatitis. Changes in institutional ownership of the company's stock can provide insights into broader market sentiment and investment trends in the sector.
The details
Sumitomo Mitsui Trust Group Inc. reduced its position in Gilead Sciences by 1.8% during the fourth quarter, bringing its total holdings to 3,269,117 shares worth $401,251,000. This represents a 0.26% ownership stake in the company.
- Sumitomo Mitsui Trust Group Inc. filed its 13F report for the fourth quarter on April 12, 2026.
- The reported changes in Gilead Sciences holdings occurred during the fourth quarter of 2025.
The players
Sumitomo Mitsui Trust Group Inc.
A major Japanese financial services group and institutional investor.
Gilead Sciences, Inc.
A leading biopharmaceutical company focused on antiviral therapies, oncology, cell therapy, and inflammatory diseases.
The takeaway
This filing provides a glimpse into the investment strategy of a major institutional investor and highlights the ongoing shifts in ownership of Gilead Sciences stock, which could signal broader trends in the biopharmaceutical industry.
